37 completed, 3 terminated, 2 unknown, 2 withdrawn. 45 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 45 | Completed 37, Terminated 3, Unknown 2, Withdrawn 2, Recruiting 1 |
| Phase 2 | 13 | Completed 9, Terminated 2, Unknown 1, Withdrawn 1 |
Follow Malabsorption Syndromes: new trials by email Literature Review of Malabsorption Syndromes trials Research Report on Malabsorption Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease HB-2121 - Celiac Disease | Phase 1 | Recruiting | Nielsen Fernandez-Becker | 20 | 2026-04-29 | 2026-07-28 |
| A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease HB-2121 - Celiac Disease, Healthy | Phase 1 | Completed | Nielsen Fernandez-Becker | 18 | 2025-08-26 | 2026-07-28 |
| A Study of PJ009 in Healthy Adult Volunteers PJ009, Placebo - Short Bowel Syndrome | Phase 1 | Completed | Chongqing Peg-Bio Biopharm Co., Ltd. | 24 | 2023-02-28 | 2024-07-29 |
| Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome Amoxicillin, Levofloxacin, Ofloxacin - Short Bowel Syndrome, Infection, Bacterial | Phase 1 | Unknown | Central Hospital, Nancy, France | 10 | 2022-12-09 | 2024-08-29 |
| A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it) Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C - Celiac Disease | Phase 1 / Phase 2 | Terminated | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | 128 | 2022-11-15 | 2026-03-10 |
| Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients DONQ52, Placebo - Celiac Disease | Phase 1 | Completed | Chugai Pharmaceutical | 56 | 2022-09-19 | 2025-01-31 |
| Study of NST-6179 in Healthy Subjects NST 6179, Placebo - Short Bowel Syndrome, Parenteral Nutrition Associated Liver Disease | Phase 1 | Completed | NorthSea Therapeutics B.V. | 70 | 2021-11-11 | 2024-06-24 |
| A Study of Guselkumab in Adult Participants With Celiac Disease Guselkumab, Placebo - Celiac Disease | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2021-06-17 | 2025-02-03 | |
| Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease Teriflunomide Oral Tablet - Celiac Disease | Phase 1 / Phase 2 | Completed | Oslo University Hospital | 15 | 2021-04-16 | 2025-05-16 |
| PTG-100 for Patients With Celiac Disease PTG-100, Placebo - Celiac Disease | Phase 1 | Completed | Nielsen Fernandez-Becker | 12 | 2021-02-26 | 2022-05-23 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole GSK3915393 Capsules, GSK3915393 Solution for Infusion, Placebo capsules - Celiac Disease, Coeliac Disease | Phase 1 | Completed | GlaxoSmithKline | 65 | 2020-11-04 | 2023-05-09 |
| Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis CALY-002, Placebo - Eosinophilic Esophagitis, Celiac Disease | Phase 1 | Completed | Calypso Biotech BV | 73 | 2020-09-28 | 2024-04-09 |
| Proof of Concept Study in Patients With Short Bowel Syndrome NM-002 - Short Bowel Syndrome | Phase 1 / Phase 2 | Unknown | 9 Meters Biopharma, Inc. | 12 | 2020-06-23 | 2020-11-20 |
| Assessment of KAN-101 in Celiac Disease (ACeD) KAN-101, Placebo - Celiac Disease | Phase 1 | Completed | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | 41 | 2020-01-21 | 2024-08-06 |
| Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support FE203799 GLP-2 analogue, FE203799 Placebo GLP-2 analogue - Short Bowel Syndrome | Phase 1 / Phase 2 | Completed | GlyPharma Therapeutics | 8 | 2018-05-08 | 2024-10-26 |
| Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency FE203799 - SBS - Short Bowel Syndrome | Phase 1 / Phase 2 | Completed | GlyPharma Therapeutics | 8 | 2018-05-02 | 2024-10-24 |
| Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease Nexvax2, Placebo - Celiac Disease, Intestinal Disease | Phase 1 | Completed | ImmusanT, Inc. | 14 | 2018-05-01 | 2018-09-20 |
| Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects RP-G28 - Lactose Intolerance | Phase 1 | Completed | Ritter Pharmaceuticals, Inc. | 14 | 2018-03-09 | 2018-08-08 |
| Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease TIMP-GLIA - Celiac Disease | Phase 1 | Completed | Takeda | 23 | 2018-01-23 | 2020-06-05 |
| Hookworm Therapy for Coeliac Disease Gluten micro-challenge, Inadvertent gluten challenge, Moderate gluten challenge - Celiac Disease | Phase 1 | Completed | James Cook University, Queensland, Australia | 54 | 2016-09-01 | 2020-02-13 |
Showing 20 of 45. Sign in to see all of them.
Celiac Disease (28) · Short Bowel Syndrome (11) · Intestinal Diseases (2) · Ancylostomiasis (1) · Autoimmune Diseases (1) · Bacterial Infections (1) · Cerebral Palsy (1) · Cholestasis (1) · Common Variable Immunodeficiency (1) · Dermatitis Herpetiformis (1) · Diarrhea (1) · Digestive System Diseases (1) · Enterocolitis, Necrotizing (1) · Eosinophilic Esophagitis (1)
Digestive System Diseases (43) · Gastrointestinal Diseases (43) · Intestinal Diseases (42) · Nutritional and Metabolic Diseases (35) · Metabolic Diseases (33) · Pathological Conditions, Signs and Symptoms (13) · Pathologic Processes (12) · Postoperative Complications (11) · Immune System Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Infections (3) · Central Nervous System Diseases (2) · Gastroenteritis (2) · Genetic Diseases, Inborn (2)
ALV003 (2) · Nexvax2 (2) · larazotide acetate (2) · ASP-1 protein, Necator americanus (1) · Aging (1) · Amoxicillin (1) · Corn Oil (1) · Diet, Gluten-Free (1) · Ensure Plus (1) · Fish Oils (1) · Glucagon-Like Peptide 2 (1) · Hu-Mik-beta-1 monoclonal antibody (1) · Itraconazole (1) · Levofloxacin (1) · Ofloxacin (1)
9 Meters Biopharma, Inc. (3) · Nielsen Fernandez-Becker (3) · Alvine Pharmaceuticals Inc. (2) · Boston Children's Hospital (2) · GlyPharma Therapeutics (2) · ImmusanT, Inc. (2) · Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Alberta Children's Hospital (1) · Amsterdam UMC, location VUmc (1) · Baylor Research Institute (1) · BioLineRx, Ltd. (1) · Calypso Biotech BV (1) · Central Hospital, Nancy, France (1) · Children's Hospital of Michigan (1)
United States (21) · Australia (7) · New Zealand (3) · United Kingdom (3) · Canada (2) · Denmark (2) · Finland (2) · Germany (2) · Netherlands (2) · Norway (2) · Belgium (1) · China (1) · France (1) · Hungary (1) · India (1)
Blake Paterson, MD (2) · Tomasz Masior (2) · Vijaya Pratha, MD (2) · Alexander Loukas, PhD (1) · Ayan Dey, Ph.D (1) · Beth Kirkpatrick, M.D. (1) · David Sigalet, MD PhD (1) · Dianne Jones, BAppSc (1) · Eric J McGrath, MD (1) · Gerhard Rogler, Prof MD PhD (1) · Greetje J Tack, MD (1) · Gregor Brown, MBBS PhD FRACP (1)
PMID 15530127, PMID 1559306, PMID 17697209, PMID 20094812, PMID 20650871, PMID 2292168, PMID 23770843, PMID 24124328, PMID 24667978, PMID 26134988, PMID 28194449, PMID 29127863, PMID 29191561, PMID 33722583, PMID 34287970, PMID 37329900, PMID 39739628, PMID 41039829, PMID 41758576, PMID 6699766, PMID 7619677, PMID 7924123, PMID 9724482
2015 (1)